VXRT 0,96$ (-36%)

die Zahlen sowie die Präsentation wurden beide während der Handelszeit veröffentlicht. Das riecht doch eher nach Kursmanipulation und anschließenden Bull Trap (After Hours), nur meine Meinung.  

Phase 1b Norovirus Boosting Regimen Study
 

Für alle Investierten tanzt Luigi jeweils pro 5 % Kursplus

ein Freudentänzchen für Euch alle hier,

also bei 11.35 % Kursplus heute zwei Luigis

______________

 

Unter dem Tisch liegen und heulen? ;-)  

Wie ich in diese Bärenfalle getappt ist, heult er Rotz und Wasser... 8-(  

eine Bullenfalle - oder?

Bärenfalle = Der Begriff kommt aus der technischen Analyse und bezeichnet ein Verkaufssignal, welches sich im Nachhinein als ein Fehlsignal erweist. Dabei setzt der Anleger auf fallende Kurse, tappt allerdings in die Falle, weil dem nicht so ist. Das Gegenteil ist die Bullenfalle.

Bullenfalle = Der Begriff kommt aus der technischen Wertpapieranalyse und bezeichnet ein Kaufsignal, welches sich im Nachhinein als ein Fehlsignal erweist. Dabei setzt der Anleger auf steigende Kurse, tappt allerdings in die Falle, weil dem nicht so ist. Das Gegenteil ist die Bärenfalle.

Selbst war ich nicht so schlau, ist aber so zu lesen beim Börsenlexikon auf finanztreff.  

Ach herrje,  natürlich meinte ich Bullenfalle *Augen verdreh* Danke das du mich darauf aufmerksam gemacht hast. Das war mehr der Hektik des Moments geschuldet denn fehlendem Wissen.

Nun ja,  letztlich keine große Posi die ich zu teuer erwarb, auch wenn es den EK nach oben trieb. Wird sich trotzdem auszahlen!
 

First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population

Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine

Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population

https://investors.vaxart.com/news-releases/...phase-1b-norovirus-dose  

richtig, es wird sich auszahlen.  

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

Piper Sandler Starts Vaxart Inc. (VXRT) at Overweight

June 11, 2021 4:16 AM
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Vaxart Inc. (NASDAQ: VXRT) with a Overweight rating and a price target of $18.00.

https://www.streetinsider.com/dr/news.php?id=18548666  

Wenn an dem Rating nur etwas Optimismus dran ist, dann könnte es ja mal mal langsam losgehen Richtung 10 Euro, lol  

denn der Kurs verläuft immer gleich zu Novavax.  

Vaxart initiated with a Buy at Jefferies

Jefferies analyst Kelechi Chikere initiated coverage of Vaxart with a Buy rating and $13 price target. Vaxart is developing oral vaccines for infectious diseases and its lead oral COVID-19 vaccine has "shown some encouraging early results," Chikere tells investors. While investor interest seems to be on COVID, Chikere is "particularly interested" in the norovirus vaccine program that the analyst said could be a $1B+ market opportunity.

https://m.thefly.com/new-landing/3325640  

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

July 7, 2021 at 8:00 AM EDT

•Milestone payments up to $130 million and royalties for global Vapendavir sales

•Vapendavir has demonstrated activity against a broad spectrum of enteroviruses

https://investors.vaxart.com/news-releases/...icense-agreement-altesa  

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

•First booster clinical study by Vaxart shows boosted immune responses similar to original responses with Vaxart vaccine

•Findings have potential implications for Vaxart's COVID-19 oral vaccine program

https://investors.vaxart.com/news-releases/...ses-subjects-previously  

FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

•Vaccine candidate expressing S-only protein produced higher serum antibodies than construct expressing both S and N in NHP study

•Phase II clinical trial with S-only candidate to begin in 2H21

•Development of this and other S-only constructs will proceed in parallel with that of S+N construct, as previously announced

SOUTH SAN FRANCISCO, Calif., Aug. 2, 2021 /PRNewswire/ -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced today that the U.S. Food and Drug Administration has cleared Vaxart's Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.

"This is great news because it allows us to move forward with our first S-only vaccine construct," said Andrei Floroiu, Vaxart's Chief Executive Officer. "As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial.

"Together, the S-only and S+N constructs are part of our unique oral tablet COVID-19 vaccine candidate portfolio, which we believe could make a significant contribution to the fight against COVID-19 globally."

"Preliminary data from our current Non-Human Primate study indicates that the S-only vaccine produced much higher serum antibodies than the one expressing both S and N proteins," said Dr. Sean Tucker, Vaxart's Chief Scientific Officer. "Our Phase I results from the S+N vaccine candidate showed remarkable T-cell responses and a mucosal antibody response, but not as strong serum antibody responses.

"This new clinical trial will allow us to compare the S-only and S+N vaccine candidates and put us in a position to decide which approach offers the best way forward for our COVID-19 vaccine development program, particularly in the face of emerging variant strains."

Vaxart announced in February that it had completed a Phase 1 clinical trial for its oral S+N COVID-19 vaccine. The results from that study found that the investigational oral vaccine triggered multiple immune responses against SARS-CoV-2 antigens, while reaching primary and secondary endpoints of safety and immunogenicity, respectively.

The Phase II clinical trial with the S-only construct is expected to start in 2H21.

https://finance.yahoo.com/news/...arts-ind-application-120000515.html

 

Vaxart Announces Creation of New Scientific and Clinical Advisory Board

August 19, 2021 at 4:02 PM EDT

https://investors.vaxart.com/news-releases/...c-and-clinical-advisory  

Vaxart announces the addition of highly regarded biotech leader Julie M. Cherrington, Ph.D. to the company’s board of directors.

Dr. Cherrington brings decades of research and development experience and executive leadership to Vaxart's Board

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the development process to commercialization…..


https://investors.vaxart.com/news-releases/...otech-executive-julie-m

 

Wie deutet du diese Zugänge an Fachpersonal?
Ist das ein Hinweis auf eine baldige mögliche Markteinführung des Corona-Impfstoffs oder bin ich da zu positiv?
 

Meiner Meinung nach ist Vaxart von einer Zulassung noch weit entfernt. Die Zugänge des Fachpersonals stimmen mich aber für die Zukunft sehr positiv. Ein Durchbruch wäre endlich mal Finanzierung, warten wir mal die weiteren Studienergebnisse ab.
Ist hier halt hochspekulativ, Daumen drücken ist angesagt!
 

hier bald zwei Stellen vor dem Komma, IMO.
 

…The booster data could be huge if the vaccine can protect against the Delta variant. In our view, the recent noravirus data where VXRT demonstrated the ability to boost the immune response in patients who had previously received the VXRT vaccine candidate bodes well for the upcoming booster data in COVID-19.

Importantly, the company has also made progress on the manufacturing front with an announcement expected by year end on the progress. VXRT has the potential to be both a major player and part of the long-term vaccine solution. The stock is a buy under $15 with a target price of $30 per share.

https://finance.yahoo.com/news/...-looks-oral-vaccines-100000588.html  

H.C. Wainwright 23rd Annual Global Investment Conference - September 13-15, 2021

https://twitter.com/vaxart/status/1435343651073372162?s=21